Alpha Cognition Inc. reports developments as a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, with ZUNVEYL oral tablets as its commercial product for Alzheimer’s disease. Company news commonly covers financial results, business updates, long-term care commercialization, and the commercial and clinical positioning of its lead assets.
Updates also address ALPHA-1062 development, including programs related to Alzheimer’s dementia and cognitive impairment with mild traumatic brain injury, as well as patent activity for traumatic brain injury applications. Other recurring announcements include investor conference participation, board composition, executive and employee equity awards, and Nasdaq-related governance disclosures.
Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) reported financial results for Q2 and H1 2024, highlighting the FDA approval of ZUNVEYL for mild-to-moderate Alzheimer's disease. The company's R&D expenses decreased to $0.9 million in Q2 and $1.9 million in H1 2024, down from $1.3 million and $2.4 million in the same periods of 2023. G&A expenses increased to $1.2 million in Q2 and $4.4 million in H1 2024, up from $0.6 million and $1.3 million in 2023. The Q2 2024 net loss was $2.1 million ($0.01 per share), and H1 2024 net loss was $7.1 million ($0.05 per share). Cash and cash equivalents stood at $1.0 million as of June 30, 2024.